Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

This study has been completed.
Information provided by:
Chroma Therapeutics Identifier:
First received: May 29, 2008
Last updated: October 21, 2010
Last verified: October 2010